Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease.
Where this comes from
- Record sourced from PubMed, PMID 39181542.
- Also identified by DOI 10.1136/bjo-2024-325527.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prior studies of teprotumumab for thyroid eye disease report proptosis reduction in millimetres, which does not fully capture teprotumumab's clinical effect since a given number of millimetres change can be of variable impact depending on patients' degree of pre-treatment proptosis. In this retrospective study analysing proptosis change as a percentage of pre-treatment proptosis among 119 patients, 208 (87.4%) eyes of 110 patients had proptosis reduction averaging 14.4% (range 2.2-40.5%) of their pre-treatment proptosis, or 3.3 mm (range 0.5-10.0 mm). Reporting proptosis reduction as a percentage of pre-treatment proptosis provides a better understanding of teprotumumab's clinical impact.
Medical subject headings
- Graves Ophthalmopathy
- Exophthalmos
- Antibodies, Monoclonal, Humanized